Table 2

Risk of death for patients with HCE and control subjects

HCEControl subjectsIRR (95% CI)P
nDeathPYRate*nDeathPYRate*
All4,5171,63419,367.7384.379,0341,69248,109.7535.172.82 (2.58–3.08)<0.0001
Age at index date (years)
 65–742,34568511,383.5860.174,72064126,966.7223.772.77 (2.45–3.13)<0.0001
 75–841,7207026,694.28104.873,47677217,438.1244.272.48 (2.21–2.79)<0.0001
 ≥854522471,289.87191.498382793,704.9175.313.20 (2.43–4.22)<0.0001
Sex
 Male2,2238609,456.9590.944,42492523,870.0438.752.51 (2.26–2.79)<0.0001
 Female2,2947749,910.7878.14,61076724,239.7131.642.81 (2.48–3.18)<0.0001
Comorbidity
 HTN2,62088210,604.6683.175,1931,01026,591.9937.982.53 (2.26–2.84)<0.0001
 Renal disease20493752.79123.543901382,023.7368.191.79 (1.33–2.41)<0.0001
 CAD8733223,776.8985.261,6723518,686.8840.412.14 (1.82–2.52)<0.0001
 Stroke7483332,795.58119.121,4434057,618.3853.162.32 (1.96–2.74)<0.0001
 Cancer3431921,018.88188.446502062,946.2869.923.05 (2.34–3.97)<0.0001
 COPD7133352,848.02117.631,3614277,096.6260.172.01 (1.72–2.36)<0.0001
 CHF268137967.82141.564961732,401.672.042.03 (1.53–2.71)<0.0001
 Liver disease3441491,393.75106.916611433,591.6939.812.76 (2.14–3.55)<0.0001
Follow-up period
 0–1 month4,517362353.6431,023.639,03431748.71041.4026.56 (17.97–39.27)<0.0001
 1–6 months4,1242471,625.52151.958,9381263,632.1934.694.54 (3.64–5.67)<0.0001
 6–12 months3,7391471,795.8481.868,5111314,141.6731.632.63 (2.07–3.33)<0.0001
 1–2 years3,4421893,212.4458.838,0372517,626.3832.911.81 (1.48–2.20)<0.0001
 2–4 years2,9673245,074.6163.857,15342612,567.8133.901.89 (1.63–2.18)<0.0001
 4–6 years2,1131903,543.1753.625,4113329,163.9736.231.49 (1.23–1.81)<0.0001
 6–8 years1,4311072,282.0346.893,8072316,143.2837.601.25 (0.99–1.57)0.0588
 ≥8 years877681,480.4845.932,3911644,085.7440.141.14 (0.86–1.52)0.3469
  • *Per 1,000 PY.